Skip to Content

Cassava Sciences, Inc.

Securities Class Action

  • Date:
  • 2/10/2025
  • Company Name:
  • Cassava Sciences, Inc.
  • Stock Symbol:
  • SAVA
  • Class Period:
  • FROM 2/7/2024 TO 11/24/2024
  • Status:
  • Filed
  • Filing Date:
  • 12/12/2024
  • Court:
  • U.S. District Court: District of Western Texas

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cassava Sciences, Inc (“Cassava” or the “Company”) (NASDAQ: SAVA) in the United States District Court for the Western District of Texas on behalf of all persons and entities who purchased or otherwise acquired Cassava securities between February 7, 2024 to November 24, 2024, both dates inclusive (the “Class Period”). Investors have until February 10, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that defendants provided investors with material information concerning Cassava’s leading drug candidate, simufilam. Defendants’ statements included, among other things, clear confidence in simufilam’s ability to treat Alzheimer’s Disease. On November 25, 2024, Cassava released topline results for the first of its two ongoing Phase 3 studies on simufilam, the “ReThink-ALZ” study. The results indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo.
 
Following this news, the price of Cassava’s common stock declined dramatically. From a closing market price of $26.48 per share on November 22, 2024, Cassava’s stock price fell to $4.30 per share on November 25, 2024, a decline of about 83.76% in the span of just a single day.
 
If you purchased or otherwise acquired Cassava shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

Contact Instructions
Please contact Brandon Walker by email at investigations@bespc.com with any questions about this case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Cassava Sciences. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: